Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer Beyond the Androgen Receptor

被引：13

作者：

Loriot, Yohann ^{[2
]}

Zoubeidi, Amina ^{[2
]}

Gleave, Martin E. ^{[1
,2
]}

机构：

[1] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada

[2] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期

关键词：

Prostate cancer; Cabazitaxel; Cabozantinib; Dasatinib; Clusterin; Hsp27; OGX-011; RANDOMIZED PHASE-II; HEPATOCYTE GROWTH-FACTOR; DOCETAXEL PLUS PREDNISONE; SRC FAMILY KINASES; EVERY; WEEKS; C-MET; ANTISENSE OLIGONUCLEOTIDE; CLINICAL-TRIALS; EPOTHILONE-B; OPEN-LABEL;

D O I：

10.1016/j.ucl.2012.07.008

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death in Western countries. Most patients with prostate cancer respond to initial androgen deprivation therapy but eventually progress to castration-resistant prostate cancer (CRPC). Although androgen receptor signaling remains the main driver in CRPC, a growing body of evidence suggests that other pathways are involved in this progression. This article reviews the preclinical data and current status of clinical trials therapeutically targeting tubulin, DNA repair, molecular chaperones such as CLU and Hsp27, tyrosine kinases, and DNA repair.

引用

页码：517 / +

页数：16

共 50 条

[21] Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies.
Mellgard, George Slade
Chakrani, Zakaria
Mccroskery, Stephen
Saffran, Nathaniel
Taylor, Nicole
Liaw, Bobby Chi-Hung
Galsky, Matt D.
Oh, William K.
Tsao, Kai
Patel, Vaibhav G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[22] Expanding Androgen- and Androgen Receptor Signaling-Directed Therapies for Castration-Resistant Prostate Cancer
Bastos, Diogo A.
Dzik, Carlos
Rathkopf, Dana
Scher, Howard I.
ONCOLOGY-NEW YORK, 2014, 28 (08): : 693 - 699
[23] Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer
Liu, Jane Jijun
Zhang, Jingsong
CANCER CONTROL, 2013, 20 (03) : 181 - 187
[24] Advances in systemic therapies for metastatic castration-resistant prostate cancer
Pant, Manish K.
Abughaban, Ahmed
Aragon-Ching, Jeanny B.
FUTURE ONCOLOGY, 2014, 10 (14) : 2213 - 2226
[25] Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor
Tilki, Derya
Schaeffer, Edward M.
Evans, Christopher P.
EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 499 - 505
[26] Androgen Receptor Targeted Therapy plus Radiotherapy in Metastatic Castration Resistant Prostate Cancer
Massaro, Maria
Facondo, Giuseppe
Vullo, Gianluca
Aschelter, Anna Maria
Rossi, Alessandro
De Sanctis, Vitaliana
Marchetti, Paolo
Osti, Mattia Falchetto
Valeriani, Maurizio
FRONTIERS IN ONCOLOGY, 2021, 11
[27] Novel targeted therapeutics for metastatic castration-resistant prostate cancer
Antonarakis, Emmanuel S.
Carducci, Michael A.
Eisenberger, Mario A.
CANCER LETTERS, 2010, 291 (01) : 1 - 13
[28] Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
MacVicar, Gary R.
Hussain, Maha H.
CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 252 - 260
[29] Androgen receptor (AR) aberrations in castration-resistant prostate cancer
Waltering, Kati K.
Urbanucci, Alfonso
Visakorpi, Tapio
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 360 (1-2) : 38 - 43
[30] Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Qin
He, Bin
FRONTIERS IN ONCOLOGY, 2019, 9

← 1 2 3 4 5 →